Drug Database
Back to search

Belgium· BE-AMP-SAM508186-00

Olumiant 2 mg

A baricitinib product containing baricitinib, registered in Belgium by Eli Lilly Nederland. The same ATC class is registered in 13 of our 19 countries.

ATC L04AF02

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedOlumiant 2 mgATCL04AF02REGISTER NO.BE-AMP-SAM508186-00PACKS LISTED3CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about baricitinibAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Baricitinib is registered in 13 of 19 countries.

Countries holding a registration under ATC L04AF02 (baricitinib), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 7 of them publish a price we can compare per daily dose
Search baricitinib products by name

Baricitinib · ATC L04AF02

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of baricitinib costs, country by country.

Normalised to the WHO defined daily dose (3 mg), the median price runs from $26.41 in France to $138.66 in United States — a ×5.2 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail
Open the full comparison — free accountDrug prices for market access

Baricitinib · price per daily dose (3 mg)

USD · FX 28 Sept 2026

  • US United States$138.66 (acquisition cost)
  • CH Switzerland$62.27
  • FR France$26.41
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Baricitinib
Manufacturer
Eli Lilly Nederland
Country
Belgium (BE)
ATC code
L04AF02
ATC class
Baricitinib
Defined daily dose
3 mg, O
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 3

2 priced
  • be_apb
    3593332
    EUR 2402.8
  • be_apb
    3593324
    EUR 910.3
  • be_apb
    7720972

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

368 interactions on record for baricitinib.

Graded by severity as the source publishes them — 295 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check baricitinib against other medicinesHow interaction checks work

Baricitinib · interactions on record

368 records

  • 295 severe
  • 67 moderate
  • 6 minor

Most severe, free to view

  • PrednisoloneA07EA01severe
  • HydrocortisoneA07EA02severe
  • PrednisoneA07EA03severe
  • BetamethasoneA07EA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Baricitinib in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All baricitinib products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • Iceland · Olumiant
  • Liechtenstein · Olumiant
  • Norway · Olumiant
  • Portugal · Baricitinib Generis

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/1b2830b1-7da9-4f3b-b8d4-7ba7e94135a0
GET /v1/drugs/1b2830b1-7da9-4f3b-b8d4-7ba7e94135a0?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Film-coated tablet",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Olumiant 2 mg",
  "name_fr": "Olumiant 2 mg",
  "name_nl": "Olumiant 2 mg",
  "amp_code": "SAM508186-00",
  "strengths": [
    "2.0000"
  ],
  "pack_count": 8,
  "substances": [
    "Baricitinib",
    "Mannitol"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Baricitinib",
  "authorisation_numbers": [
    "EU/1/16/1170/001",
    "EU/1/16/1170/003",
    "EU/1/16/1170/002",
    "EU/1/16/1170/005",
    "EU/1/16/1170/004",
    "EU/1/16/1170/007",
    "EU/1/16/1170/006",
    "EU/1/16/1170/008"
  ]
}
API referenceMCP serverPlans

See everything about baricitinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console